COVID-19 in patients with chronic inflammatory rheumatic diseases: Do these patients have a higher risk of COVID-19 due to their underlying medication?

Q4 Medicine
Claudia Dragomir, A. Burlui, Geanina-Florica Popescu, Ioan-Teodor Dragoi, A. Cardoneanu, L. Macovei, E. Rezus
{"title":"COVID-19 in patients with chronic inflammatory rheumatic diseases: Do these patients have a higher risk of COVID-19 due to their underlying medication?","authors":"Claudia Dragomir, A. Burlui, Geanina-Florica Popescu, Ioan-Teodor Dragoi, A. Cardoneanu, L. Macovei, E. Rezus","doi":"10.37897/rjr.2021.2.1","DOIUrl":null,"url":null,"abstract":"Since the first case was reported to the World Health Organization (in late December 2019 in Wuhan, Hubei Province, China), by mid-June 2021, there have been 175,541,600 confirmed cases of COVID-19 globally, including 3,798,361 reported deaths. Many of those infected with SARS-CoV-2 have an asymptomatic form of the disease or mild flu-like symptoms. In another category of patients, the disease may be more aggressive, with a severe form that can lead to acute respiratory distress syndrome (ARDS), respiratory failure, and even death with a negative impact on patients. The COVID-19 pandemic has arisen serious concerns in the rheumatology community regarding the management of immunosuppressed patients diagnosed with inflammatory rheumatic diseases. It has been stated that severe forms of COVID-19 occur as a result of exacerbated inflammation status and cytokine production. Nevertheless, it remains unclear whether the use of biological agents subjects the patient to a higher risk, or rather protects them against severe forms of the disease. According to the American College of Rheumatology, rheumatic diseases were not identified as a risk factor that predicted poor outcome in patients with COVID-19. However, various studies have certified that corticosteroid treatment in patients with chronic rheumatic diseases at a dose >10 mg/day is associated with an increased risk of infection as well as the possibility of developing more severe COVID-19 symptoms.","PeriodicalId":33518,"journal":{"name":"Revista Romana de Reumatologie","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Romana de Reumatologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37897/rjr.2021.2.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Since the first case was reported to the World Health Organization (in late December 2019 in Wuhan, Hubei Province, China), by mid-June 2021, there have been 175,541,600 confirmed cases of COVID-19 globally, including 3,798,361 reported deaths. Many of those infected with SARS-CoV-2 have an asymptomatic form of the disease or mild flu-like symptoms. In another category of patients, the disease may be more aggressive, with a severe form that can lead to acute respiratory distress syndrome (ARDS), respiratory failure, and even death with a negative impact on patients. The COVID-19 pandemic has arisen serious concerns in the rheumatology community regarding the management of immunosuppressed patients diagnosed with inflammatory rheumatic diseases. It has been stated that severe forms of COVID-19 occur as a result of exacerbated inflammation status and cytokine production. Nevertheless, it remains unclear whether the use of biological agents subjects the patient to a higher risk, or rather protects them against severe forms of the disease. According to the American College of Rheumatology, rheumatic diseases were not identified as a risk factor that predicted poor outcome in patients with COVID-19. However, various studies have certified that corticosteroid treatment in patients with chronic rheumatic diseases at a dose >10 mg/day is associated with an increased risk of infection as well as the possibility of developing more severe COVID-19 symptoms.
慢性炎性风湿性疾病患者中的新冠肺炎:这些患者是否因其潜在药物而患新冠肺炎的风险更高?
自向世界卫生组织报告第一例病例(2019年12月底在中国湖北省武汉市)以来,截至2021年6月中旬,全球新冠肺炎确诊病例已达175541600例,其中死亡3798361例。许多感染严重急性呼吸系统综合征冠状病毒2型的人都有无症状的疾病或轻微的流感样症状。在另一类患者中,这种疾病可能更具攻击性,其严重形式可能导致急性呼吸窘迫综合征(ARDS)、呼吸衰竭,甚至死亡,对患者产生负面影响。新冠肺炎大流行引起了风湿病界对诊断为炎性风湿性疾病的免疫抑制患者的管理的严重关注。有人指出,严重形式的新冠肺炎是由于炎症状态恶化和细胞因子产生而发生的。然而,目前尚不清楚生物制剂的使用是否会使患者面临更高的风险,或者更确切地说,是保护他们免受严重疾病的影响。根据美国风湿病学会的数据,风湿性疾病未被确定为预测新冠肺炎患者预后不良的危险因素。然而,各种研究证明,慢性风湿性疾病患者的皮质类固醇治疗剂量>10 mg/天与感染风险增加以及出现更严重新冠肺炎症状的可能性有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.10
自引率
0.00%
发文量
22
审稿时长
4 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信